Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation

Peng, Cheng Yuan; Chen, Chih Bin; Lai, Hsueh Chou; Su, Wen Pang; Chuang, Po‐Heng; Wu, Hanwei; Jeng, Long Bin

doi:10.1007/s12072-010-9227-x

Cited by 6 publications

(6 citation statements)

References 30 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The COBAS Amplicor HBV monitor test (lower limit of detection, 50 IU/mL; Roche Diagnostic Systems, Branchburg, NJ, USA) and COBAS AmpliPrep‐COBAS TaqMan HBV test (lower limit of detection, 12 IU/mL; Roche Diagnostic Systems) were used before and after August 2008 respectively. HBV genotyping was performed as previously described …”

Section: Methodsmentioning

confidence: 99%

Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long‐term nucleos(t)ide analogue therapy

Hsu

Chen

Lai

et al. 2017

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long‐term nucleos(t)ide analogue therapy

Hsu

Chen

Lai

et al. 2017

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most of these studies (14/15) were related to LAM. Of the 14 studies evaluating LAM, 6 were open-label studies, 4 compared LAM to untreated or historical controls, 2 compared LAM in CHB patients between with or without AE, and 2 compared LAM to entecavir (ETV) as historical controls [6], [7], [8], [10], [11], [13], [14], [15], [16], [17], [18], [19], [20], [21]. Both of the 2 studies evaluating ETV had a historical control group of LAM [10], [21].…”

Section: Resultsmentioning

confidence: 99%

“…Another study from Taiwan suggested that LAM treatment had definite survival benefit among patients with low baseline serum bilirubin level (<20 mg/dL) [6]. It is also noted that good virological and biochemical responses have been achieved in the patients with AE of CHB who received NAs therapies [9], [10], [11]. It was estimated that patients with a pre-therapy ALT level over 5 × ULN appeared to have a rate of hepatitis B e antigen (HBeAg) seroconversion as high as 64% after 1 year of LAM therapy [12].…”

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of Nucleos(t)ide Analogues in Patients with Spontaneous Acute Exacerbation of Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Zhao

Shen

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundSpontaneous acute exacerbation (AE) of chronic hepatitis B (CHB) is often detrimental but sometimes leads to sustained immune control and disease remission. The efficacy and safety of nucleos(t)ide analogues (NAs) in patients with spontaneous AE of CHB remains unclear.MethodsWe performed a systematic review and meta-analysis of NAs in patients with spontaneous AE of CHB. We calculated pooled effects of NAs in these patients of each study and conducted quantitative meta-analysis, displaying results using Forest plots.Results15 studies were included and substantial heterogeneity was noted in the inclusion/exclusion criteria and controls. Pooled data showed no benefit of lamivudine (LAM) vs. untreated controls for transplant-free survival in patients with spontaneous AE of CHB (OR = 0.98 (95% CI, 0.50–1.92; P = 0.956)), hepatic decompensation (OR = 0.94 (95% CI, 0.47–1.88; P = 0.862)) and liver failure owing to AE (OR = 2.30 (95% CI, 0.35–15.37; P = 0.387)) at 3 months. Entecavir achieved even higher short-term mortality than LAM. NAs led to rates of ALT normalization, undetectable HBV DNA, HBeAg loss, HBeAg seroconversion and drug resistance at 1 year in 88%, 61%, 46%, 35% and 5%. Pooled data also showed benefit favoring LAM vs. untreated controls for ALT normalization (OR = 1.98 (95% CI, 1.03–3.80; P = 0.039)) and undetectable HBV DNA (OR = 38.50 (95% CI, 7.68–192.99; P<0.001)) at 3 months. All NAs were relatively safe and well tolerated.ConclusionNAs had no obvious impact on short-term survival in patients with AE of CHB, despite of possible better antiviral responses. We suggest additional studies to evaluate the efficacy of other NAs and early introduction of immunosuppressant in combination with NAs. We highlight developing prognostic models to identify predictors of mortality and disease progression for AE of CHB.

show abstract

“…However, the role of gender in the disparity of HBeAg burden is not fully known. While female gender has been reported to be an independent predictor of HBeAg clearance following HBV therapy [30], some studies that focused on spontaneous HBeAg seroconversion in the absence of HBV therapy found that male gender was more likely to be associated with HBeAg clearance [31,32]. It is not clear if these contrasting observations are actually due to gender differences or differences in infecting genotypes.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria

Iroezindu

Daniyam

Agbaji

et al. 2013

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Human immunodeficiency virus (HIV) negatively impacts the natural history of hepatitis B virus (HBV) infection, including replication. We determined the prevalence of HBeAg in HIV/HBV co-infected patients compared to HBV mono-infected controls and further investigated the relationship between HBeAg seropositivity and the degree of HIV-induced immunosuppression in co-infected patients. Methodology: The study design was cross-sectional. One hundred HBsAg-positive HIV-infected adults and 100 age and sex matched HBsAg-positive HIV negative controls were consecutively recruited between May and November 2010. Relevant demographic and HBVrelated information was obtained. HBeAg was assayed by semi-quantitative third generation ELISA. The HIV/HBV co-infected patients also had CD4+ cell and HIV viral load quantification measured using flow cytometry and polymerase chain reaction techniques respectively. Results: In each group, the mean age was 34 ± 8 years and the majority (61%) was female. The prevalence of HBeAg was significantly higher among co-infected patients (n = 28; 28%) than in the controls (n = 15; 15%; p = 0.03). HBeAg seropositivity was independently associated with age < 40 years (AOR = 2.83, 95% = CI 1.29-6.17) and HIV seropositivity (AOR = 2.44, 95% C.I = 1.17-5.07). The prevalence of HBeAg was significantly higher in co-infected patients with CD4 cell count < 200 cell/µL (41.3%) compared to those with 200-499 cell/µL (18.6%) and ≥500 cell/µL (9.1%), p = 0.006. Conclusion: HIV/HBV co-infected patients have a significantly higher prevalence of HBeAg than HBV mono-infected individuals. HBVinfected patients should be routinely assessed for HBeAg, especially if they are co-infected with HIV.

show abstract

Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation

Abstract: The online version of this article (doi:10.1007/s12072-010-9227-x) contains supplementary material, which is available to authorized users.

Cited by 6 publications

References 30 publications

Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long‐term nucleos(t)ide analogue therapy

Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long‐term nucleos(t)ide analogue therapy

The Efficacy and Safety of Nucleos(t)ide Analogues in Patients with Spontaneous Acute Exacerbation of Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Prevalence of hepatitis B e antigen among human immunodeficiency virus and hepatitis B virus co-infected patients in Jos, Nigeria

Contact Info

Product

Resources

About